UCB continues search for an effective Lupus treatment

Written by DS on in the category news.

The lupus drug, epratuzumab, developed by UCB stumbled in the third and final test phase. Patients who were administered the agent in combination with the standard therapy, did not react significantly better than patients in whom standard therapy was supplemented with a placebo.

Lupus is an autoimmune disease, which leads to inflammatory reactions in the skin. The biopharmaceutical company has invested in epratuzumab for almost a decade, demonstrating the efforts UCB takes to combat the disease and push innovation forward.

Late stage trials are not fail-proof; success is estimated around 50% and show the importance of a broad R&D portfolio. UCB announced that it continues to search for better treatment of lupus and says that another compound is already in development. 3 other flagship drugs from UCB performed very well.

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

UGent Janssen Turnstone XpandInnovation V-Bio Ventures Itera Life Science Flanders.bio Biowin GSK KU Leuven

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.